x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com
Alzheimer's

Nov2022

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ​

• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed

Read More
Parkinson’s

Oct2022

Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73)

Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73) Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France – Ariana Pharma, the leading Al-driven precision medicine company, […]

Read More
Recent Posts

Jul2022

Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer

Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. […]

Read More
Publications Cancer Precision Medicine

Jun2022

Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.

Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]

Read More
Precision Medicine Parkinson’s

Mar2022

Anavex Life Sciences and Ariana Pharma present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference

Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Ariana, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.

Read More
Precision Medicine

Feb2022

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment

Read More
Precision Medicine
Ariana Pharma - Img

May2021

Ariana appoints pharmaceutical industry drug development veteran

Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas

Read More
Autoimmune disease Precision Medicine
Ariana Pharma - Img

May2021

Ariana announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi

The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases.

Read More
Precision Medicine
Ariana Pharma - Img

May2021

Ariana Announces Appointment of Accomplished Business and Strategy Executive, Kia Motesharei to its Board of Directors.

Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.

Read More
Alzheimer's
Ariana Pharma - Img

Apr2020

Towards a first precision medicine treatment of Alzheimer’s disease using Ariana’s Explainable AI.

Paris and Boston, April 17th 2020. Ariana® Pharma, a leading digital health company announced today the publication of the first reported genome-wide search for biomarkers associated with drug response in Alzheimer’s disease in the Alzheimer’s & Dementia: Translational Research & Clinical Interventions journal. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, […]

Read More

Posts navigation

1 2 3 4 … 7

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved